Black Diamond Therapeutics, Inc.
An oncology drug developer, Black Diamond Therapeutics makes small-molecule medicines that treat whole 'families' of cancer-causing mutations with a single therapy, rather than one mutation at a time. Its lead experimental drug, BDTX-1535, can cross the blood-brain barrier to reach hard-to-treat brain tumors like glioblastoma. Co-founded in 2016 by scientists David Epstein and Elizabeth Buck, the company began as ASET Therapeutics before taking the Black Diamond name — a rebrand with no public origin story.
Bought 894.7K · Sold 350.0K
Granted 443 · Bought 1.00M
Bought 894.7K · Sold 571.6K
Granted 102.5K · Bought 1.80M
Bought 935.9K
Bought 4.78M · Sold 5.78M
Granted 14.5K · Sold 73.0K
Bought 400.0K
Granted 75.0K
Bought 81.4K
Granted 121.5K
Granted 85.2K
Granted 124.6K · Bought 3.0K · Sold 44.2K
Granted 75.0K
Granted 45.0K
Granted 37.9K · Bought 5.0K
Granted 38.1K
Granted 10.0K
Granted 8.9K
Granted 30.7K · Sold 27.5K
Granted 15.0K · Sold 15.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Bolzon Bradley J PhDDirector, 10% owner · 182 transactions | — | 38.84Mas of Dec 2020 | — | 894.7K | 350.0K |
| Shah Rajeev M.Director · 12 transactions | — | 7.46Mas of May 2021 | 443 | 1.00M | — |
| Versant Vantage I, L.P. +3 co-filers10% owner · 166 transactions | — | 6.21Mas of Aug 2024 | — | 894.7K | 571.6K |
| Behbahani AliDirector · 26 transactions | — | 4.55M | 102.5K | 1.80M | — |
| Kolchinsky Peter +4 co-filersDirector · 1 transaction | — | 3.53Mas of Jul 2023 | — | 935.9K | — |
| BB Biotech Ag +1 co-filer10% owner · 22 transactions | — | 3.23Mas of Mar 2025 | — | 4.78M | 5.78M |
| Epstein David M.SEE REMARKS, Director · 16 transactions | — | 936.6Kas of Jun 2023 | 14.5K | — | 73.0K |
| Deerfield Management Company, L.P. (Series C) +3 co-filersReporting owner · 2 transactions | — | 778.8Kas of Feb 2020 | — | 400.0K | — |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P.10% owner · 1 transaction | — | 568.2Kas of Feb 2020 | — | — | — |
| Buck ElizabethCHIEF SCIENTIFIC OFFICER · 1 transaction | — | 170.2Kas of Jan 2025 | 75.0K | — | — |
| Ni FangSEE REMARKS · 3 transactions | — | 125.4Kas of Dec 2022 | — | 81.4K | — |
| Velleca Mark A.PRESIDENT & CEO, Director · 8 transactions | — | 121.5Kas of Jan 2025 | 121.5K | — | — |
| Jones ErikaSEE REMARKS · 3 transactions | — | 85.2Kas of Jan 2025 | 85.2K | — | — |
| Hatzis-Schoch BrentSEE REMARKS · 35 transactions | — | 83.4Kas of Jan 2025 | 124.6K | 3.0K | 44.2K |
| Menzel Garry EDirector · 1 transaction | — | 76.6Kas of Feb 2020 | — | — | — |
| Yurasov SergeyCHIEF MEDICAL OFFICER · 1 transaction | — | 75.0Kas of Jan 2025 | 75.0K | — | — |
| Raman PrakashDirector · 9 transactions | — | 45.0K | 45.0K | — | — |
| Ingram Robert AlexanderFORMER DIRECTOR · 10 transactions | — | 42.9Kas of Dec 2022 | 37.9K | 5.0K | — |
| Dixon Wendy LDirector · 8 transactions | — | 38.1Kas of Mar 2024 | 38.1K | — | — |
| Humphrey RachelChief Medical Officer · 1 transaction | — | 10.0Kas of Sep 2020 | 10.0K | — | — |
| Campbell ShannonDirector · 3 transactions | — | 8.9Kas of Dec 2024 | 8.9K | — | — |
| Roberts Christopher D.Chief Scientific Officer · 25 transactions | — | 3.2Kas of May 2021 | 30.7K | — | 27.5K |
| Leggett ThomasChief Financial Officer · 11 transactions | — | 0as of Jan 2021 | 15.0K | — | 15.0K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: +3.93M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.